Have a feature idea you'd love to see implemented?
Let us know!
ADIL Adial Pharmaceuticals Inc
Price (delayed)
$1.07
Market cap
$6.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.9
Enterprise value
$1.65M
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist,
Highlights
ADIL's equity has soared by 152% YoY and by 38% QoQ
The company's EPS rose by 32% YoY and by 17% QoQ
Adial Pharmaceuticals's net income has plunged by 115% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of ADIL
Market
Valuations
Earnings
Shares outstanding
6.41M
Market cap
$6.85M
Enterprise value
$1.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$13.05M
EBIT
-$13.05M
EBITDA
-$13.05M
Free cash flow
-$6.69M
Per share
Balance sheet
Liquidity
EPS
-$3.9
EPS diluted
-$3.9
Free cash flow per share
-$1.15
Book value per share
$0.92
Revenue per share
$0
TBVPS
$1.15
Total assets
$6.71M
Total liabilities
$829,046
Debt
$0
Equity
$5.88M
Working capital
$4.79M
Debt to equity
0
Current ratio
6.78
Quick ratio
6.28
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-226.1%
Return on equity
-256.3%
Return on invested capital
-1,302.7%
Return on capital employed
-221.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADIL stock price
How has the Adial Pharmaceuticals stock price performed over time
Intraday
1.9%
1 week
-1.83%
1 month
4.9%
1 year
-38.15%
YTD
-42.47%
QTD
7.11%
Financial performance
How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.13M
Net income
-$13.05M
Gross margin
N/A
Net margin
N/A
Adial Pharmaceuticals's net income has plunged by 115% YoY and by 7% from the previous quarter
The operating income has declined by 12% since the previous quarter and by 6% year-on-year
Growth
What is Adial Pharmaceuticals's growth rate over time
Valuation
What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 32% YoY and by 17% QoQ
ADIL's equity has soared by 152% YoY and by 38% QoQ
The stock's price to book (P/B) is 74% less than its 5-year quarterly average of 4.4 but 45% more than its last 4 quarters average of 0.8
Efficiency
How efficient is Adial Pharmaceuticals business performance
The ROIC has shrunk by 103% YoY and by 42% QoQ
ADIL's return on assets has dropped by 52% year-on-year but it is up by 11% since the previous quarter
ADIL's ROE is up by 12% QoQ but it is down by 9% YoY
Dividends
What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADIL.
Financial health
How did Adial Pharmaceuticals financials performed over time
The company's total assets has surged by 134% YoY and by 36% QoQ
Adial Pharmaceuticals's total liabilities has soared by 57% YoY and by 23% from the previous quarter
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity has soared by 152% YoY and by 38% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.